NRXP insider filings

NRX Pharmaceuticals, Inc. — 47 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-04. Screen NRXP transaction legs live →

Insider transaction summary — last 90 days

2026-08-23 to 2026-11-21, from the filings listed below: 2 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By insider — same window

Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

InsiderFilingsPurchases (P)Sales (S)Other legs
ABRAMS MICHAEL S — Chief Financial Officer1——1
Javitt Jonathan C — CEO and Chairman, Director1——1

Recent insider filings — NRX Pharmaceuticals, Inc.

FiledFormInsiderReported transactionsSource
2026-11-044Javitt Jonathan C — CEO and Chairman, DirectorGrant/award (A): 150,000 (derivative) @ $0EDGAR
2026-11-044ABRAMS MICHAEL S — Chief Financial OfficerGrant/award (A): 75,000 (derivative) @ $0EDGAR
2026-02-174Casper Joseph Michael — Chief Operating OfficerGrant/award (A): 100,000 (derivative) @ $0EDGAR
2025-09-104McBride Dennis — DirectorGrant/award (A): 25,000 (derivative) @ $0EDGAR
2025-09-104Flynn Patrick John — DirectorGrant/award (A): 50,000 (derivative) @ $0EDGAR
2025-09-104Hurvitz Chaim — DirectorGrant/award (A): 25,000 (derivative) @ $0EDGAR
2025-09-104Javitt Jonathan C — Chairman and Chief Scientist, Director, 10% ownerGrant/award (A): 125,000 (derivative) @ $0EDGAR
2025-02-114ABRAMS MICHAEL S — Chief Financial OfficerGrant/award (A): 50,000 (derivative) @ $0EDGAR
2024-12-184Javitt Jonathan C — Chairman and Chief Scientist, Director, 10% ownerPurchase (P): 40,000 @ $1.17EDGAR
2023-09-114Gorovitz Aaron — DirectorPurchase (P): 35,000 @ $0.32EDGAR
2023-09-114Hurvitz Chaim — DirectorPurchase (P): 70,000 @ $0.29EDGAR
2023-08-244Javitt Jonathan C — Chief Scientist, Director, 10% ownerPurchase (P): 100,000 @ $0.33EDGAR
2023-08-234Javitt Jonathan C — Chief Scientist, Director, 10% ownerPurchase (P): 200,000 @ $0.32EDGAR
2022-12-194Willard Stephen H — CHIEF EXECUTIVE OFFICER, DirectorPurchase (P): 50,000 @ $1.17EDGAR
2022-12-194VAN VOORHEES SETH — CHIEF FINANCIAL OFFICERPurchase (P): 30,000 @ $1.10EDGAR
2022-12-194/AVAN VOORHEES SETH — CHIEF FINANCIAL OFFICERPurchase (P): 8,716 @ $1.12 · Purchase (P): 600 @ $1.10 · Purchase (P): 7,021 @ $1.11EDGAR
2022-12-094Javitt Jonathan C — Director, 10% ownerSale (S): 400,000 @ $1EDGAR
2022-12-014Javitt Daniel C. — 10% ownerSale (S): 13,730 @ $1.50 · Sale (S): 8,441 @ $1.50EDGAR
2022-11-294Flynn Patrick John — DirectorPurchase (P): 2,500 @ $1.25 · Purchase (P): 2,500 @ $1.25 · Purchase (P): 2,500 @ $1.25 · Purchase (P): 2,500 @ $1.24 · Purchase (P): 1,750 @ $1.25EDGAR
2022-11-284VAN VOORHEES SETH — CHIEF FINANCIAL OFFICERPurchase (P): 8,716 @ $1.12 · Purchase (P): 600 @ $1.10 · Purchase (P): 7,021 @ $1.11EDGAR
2022-11-234/AHurvitz Chaim — DirectorPurchase (P): 287,812 @ $0.99 · Purchase (P): 171,780 @ $1.08 · Purchase (P): 40,408 @ $1.10EDGAR
2022-11-224Gorovitz Aaron — DirectorGrant/award (A): 162,660 (derivative)EDGAR
2022-11-224Glied Sharon — DirectorGrant/award (A): 162,660 (derivative)EDGAR
2022-11-224Flynn Patrick John — DirectorGrant/award (A): 162,660 (derivative)EDGAR
2022-11-214Hurvitz Chaim — DirectorPurchase (P): 287,812 @ $0.99 · Purchase (P): 171,780 @ $1.08 · Purchase (P): 40,408 @ $1.10 · Grant/award (A): 162,660 (derivative)EDGAR
2022-11-184Javitt Daniel C. — 10% ownerSale (S): 133,719 @ $1.02 · Sale (S): 33,018 @ $1.05EDGAR
2022-11-154Javitt Daniel C. — 10% ownerSale (S): 49,200 @ $1.01EDGAR
2022-08-024Javitt Daniel C. — 10% ownerSale (S): 784,063 @ $1.01EDGAR
2022-07-054Javitt Daniel C. — 10% ownerGift (G): 2,000,000 @ $0EDGAR
2022-06-074Javitt Daniel C. — 10% ownerSale (S): 243,596 @ $0.70 · Sale (S): 115,657 @ $0.67 · Sale (S): 86,459 @ $0.65EDGAR
2022-06-024Javitt Jonathan C — Chief Scientist, Director, 10% ownerPurchase (P): 100,000 @ $58EDGAR
2022-06-024/AJavitt Jonathan C — Chief Scientist, Director, 10% ownerPurchase (P): 100,000 @ $0.58EDGAR
2022-03-104Besthof Robert — Interim CEOGrant/award (A): 100,000 (derivative) @ $2.61EDGAR
2021-11-024McMaster Herbert Raymond — DirectorOption exercise (M): 18,300 @ $2.22 · Conversion (C): 28,724 (derivative) @ $2.22 · Grant/award (A): 10,424 (derivative) @ $0EDGAR
2021-11-024Javitt Daniel C. — 10% ownerGift (G): 434,594 · Gift (G): 434,594EDGAR
2021-11-024Daigneault Alessandra — General Counsel & SecretaryOption exercise (M): 27,395 @ $3.07 · Sale (S): 33,715 @ $13.11 · Option exercise (M): 18,420 @ $3.07 · Option exercise (M): 13,164 @ $3.07 · Conversion (C): 43,000 (derivative) @ $3.07 · Grant/award (A): 15,605 (derivative) @ $0 · +4 moreEDGAR
2021-11-024Besthof Robert — Chief Comm. & Patient OfficerOption exercise (M): 63,710 @ $0.20 · Sale (S): 40,000 @ $11.76 · Conversion (C): 100,000 (derivative) @ $0.20 · Grant/award (A): 36,290 (derivative) @ $0EDGAR
2021-06-104Javitt Daniel C. — 10% ownerGrant/award (A): 13,971,864EDGAR
2021-06-104Gorovitz Aaron — DirectorGrant/award (A): 8,336 · Grant/award (A): 8,336 · Grant/award (A): 8,336 · Grant/award (A): 16,678EDGAR
2021-06-104Glied Sharon — DirectorGrant/award (A): 13,168 · Grant/award (A): 65,437 (derivative)EDGAR
2021-06-104Fricker William — CFO & TreasurerGrant/award (A): 99,200 (derivative) · Grant/award (A): 99,200 (derivative)EDGAR
2021-06-104Flynn Patrick John — DirectorGrant/award (A): 362,332 · Grant/award (A): 35,209 · Grant/award (A): 35,209 · Grant/award (A): 692,639 (derivative) · Grant/award (A): 692,639 (derivative)EDGAR
2021-06-104Daigneault Alessandra — General Counsel & SecretaryGrant/award (A): 6,320 · Grant/award (A): 143,840 (derivative) · Grant/award (A): 49,600 (derivative) · Grant/award (A): 148,800 (derivative)EDGAR
2021-06-104Besthof Robert — Chief Comm. & Patient OfficerGrant/award (A): 347,200 (derivative) · Grant/award (A): 347,200 (derivative)EDGAR
2021-06-104Hurvitz Chaim — DirectorGrant/award (A): 1,436,350 · Grant/award (A): 208,443 · Grant/award (A): 218,423 (derivative)EDGAR
2021-06-104Troy Daniel — DirectorGrant/award (A): 43,093 · Grant/award (A): 65,437 (derivative)EDGAR
2021-06-104Javitt Jonathan C — Chief Executive Officer, Director, 10% ownerGrant/award (A): 46,332 · Grant/award (A): 13,348,997 · Grant/award (A): 1,422,000EDGAR

Recent 8-K events — NRX Pharmaceuticals, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-028-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-10-168-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-10-058-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-168-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-148-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-178-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-078-K7.01 — Regulation FD DisclosureEDGAR
2026-07-228-K8.01 — Other EventsEDGAR
2026-06-048-K1.01 — Entry into a Material Definitive Agreement
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-028-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=NRXP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs